about
Clostridium difficile in the ICU: the struggle continuesTrends in Clostridium difficile Disease: Epidemiology and InterventionSafety and Durability of RBX2660 (Microbiota Suspension) for Recurrent Clostridium difficile Infection: Results of the PUNCH CD Study.Infections in Hematopoietic Cell Transplant Recipients: Results From the Organ Transplant Infection Project, a Multicenter, Prospective, Cohort StudyRisk factors for recurrent Clostridium difficile infection (CDI) hospitalization among hospitalized patients with an initial CDI episode: a retrospective cohort study.Prevalence and risk factors for asymptomatic Clostridium difficile carriage.Multicenter study of the impact of community-onset Clostridium difficile infection on surveillance for C. difficile infection.A Clostridium difficile infection "intervention": change in toxin assay results in fewer C difficile infection cases without changes in patient outcomes.Strategies to prevent Clostridium difficile infections in acute care hospitals: 2014 Update.Introduction to "A Compendium of Strategies To Prevent Healthcare-Associated Infections in Acute Care Hospitals: 2014 updates"A compendium of strategies to prevent healthcare-associated infections in acute care hospitals: 2014 updates.Assessment of an alternative meropenem dosing strategy compared with imipenem-cilastatin or traditional meropenem dosing after cefepime failure or intolerance in adults with neutropenic fever.Strategies to prevent catheter-associated urinary tract infections in acute care hospitals.The impact of ICD-9-CM code rank order on the estimated prevalence of Clostridium difficile infectionsPhenotypic and genotypic analysis of Clostridium difficile isolates: a single-center study.Impact of clinical symptoms on interpretation of diagnostic assays for Clostridium difficile infections.ICD-9 codes and surveillance for Clostridium difficile-associated diseaseRisk Factors for Acquisition and Loss of Clostridium difficile Colonization in Hospitalized Patients.Identification of Medicare Recipients at Highest Risk for Clostridium difficile Infection in the US by Population Attributable Risk Analysis.The burden of clostridium difficile infection: estimates of the incidence of CDI from U.S. Administrative databasesEpidemiological and economic burden of Clostridium difficile in the United States: estimates from a modeling approach.Burden of Clostridium difficile on the healthcare system.Clostridium difficile-associated disease in allogeneic hematopoietic stem-cell transplant recipients: risk associations, protective associations, and outcomes.Randomized Controlled Trial to Determine the Impact of Probiotic Administration on Colonization With Multidrug-Resistant Organisms in Critically Ill Patients.Infections after Transplantation of Bone Marrow or Peripheral Blood Stem Cells from Unrelated Donors.MAPK-activated protein kinase 2 contributes to Clostridium difficile-associated inflammationHospital-associated Clostridium difficile infection: is it necessary to track community-onset disease?Quantifying Transmission of Clostridium difficile within and outside Healthcare Settings.Multicenter study of surveillance for hospital-onset Clostridium difficile infection by the use of ICD-9-CM diagnosis codesMulticenter study of Clostridium difficile infection rates from 2000 to 2006Clostridium difficile infection: a re-emerging threat.Implementing automated surveillance for tracking Clostridium difficile infection at multiple healthcare facilities.Development and validation of a Clostridium difficile infection risk prediction model.A multicenter study of Clostridium difficile infection-related colectomy, 2000-2006.Recognition and prevention of hospital-associated enteric infections in the intensive care unitFrequent hospital readmissions for Clostridium difficile infection and the impact on estimates of hospital-associated C. difficile burden.Use of cytomegalovirus intravenous immune globulin for the adjunctive treatment of cytomegalovirus in hematopoietic stem cell transplant recipients.Attributable outcomes of endemic Clostridium difficile-associated disease in nonsurgical patients.Prevention and treatment of cancer-related infections.Micafungin for the prophylaxis and treatment of Candida infections.
P50
Q26823000-878248A7-1EC0-47E8-9343-D4E95059F4F2Q28655729-91D0BED0-7FC4-448A-B4FE-BBB73D2F9EEAQ33466550-F842D459-6A82-4B06-97E0-65C15B3BCB5BQ33641898-B7BA5630-ACED-4B21-8C95-FBCF1EA76AA8Q33729925-BC017661-32C3-4128-AA1E-0E03F4C5E909Q34048138-45AEF3B3-33F0-453B-B198-E25F9CEA6D30Q34141945-452D008E-5C12-4C81-964B-1CA5C6E97756Q34142574-A27C7158-D936-4B51-B392-812FA456589AQ34419009-65A03812-AFCF-4A71-8C69-DEBCFA2BD80AQ34440749-B647CEC1-6DF0-46FF-90FE-EFC9AFA18807Q34470266-86E78931-262E-4F86-A748-DAC50EF76543Q34632953-4F12430A-BD8B-4F96-A936-3E94FC860705Q34847637-9F82AABE-C32B-4375-8455-376B2B3087F4Q35031682-0113338F-69AF-4371-91E1-F4A043E8950CQ35036237-3FDFC642-F15B-403B-A54D-F2111DCCBE10Q35139786-C4C7815E-5B53-4E9A-BBB2-0FF72428E974Q35792132-D0AF378C-017A-4FB0-B0C8-C20BE1794A8CQ35860076-9A9A669C-7884-46B9-BB29-0D3C1EFFB9D7Q35918139-4ED99358-818E-4223-9160-7CC7EF652443Q35996524-91300F36-5F42-479F-B011-373532343251Q36055810-6E866199-F608-4BF9-974A-F25B82F0DB17Q36071497-8FC675E2-3F56-4DB8-B4EB-E6F2AF7F6199Q36077707-B9E3D997-6F8F-4C77-AA12-03295D409425Q36399668-CCE28397-6BCE-494D-93F3-37FDA9F396E5Q36473993-6C147DED-CE57-4E75-A05C-8D4A751E8448Q36646782-6D1CB759-2E5B-4C1D-97B6-448C258E3D80Q36687670-F77A693E-767C-4F89-97B8-E80779F98D16Q36726659-566CD577-D170-4323-9100-D3293CFC92ECQ36808157-57D64994-98A2-4C51-AE88-914EC031B663Q36827517-D9C7680F-DCFF-4EAF-B8E1-FF1C02E78B15Q36827540-79F9EC9C-A5E7-4909-BF0C-E1E9CA048177Q36831094-7BD86F7A-6C76-48B5-923E-8018D9C7EE9AQ36831098-752EFED9-C649-4A82-8BFB-50CD5C6E661FQ36853751-E4A85ECD-8C56-404C-A688-3A700F918B11Q36853756-38852465-F6E7-41AF-A699-6076FFF7D505Q36853764-91BC610E-6E20-4D44-B9A5-6C60D1717F15Q36889236-F5CD3E1C-B61D-4D54-A5A4-B0D5D2768372Q37009389-AA95496E-481C-42E6-B52B-FFCC29D485CFQ37101802-D6C8A3A8-25E7-40D8-AEB0-D5960110BA01Q37124868-63D24E18-D3DF-40D8-AC38-FFE92CCB68D4
P50
name
Erik R Dubberke
@ast
Erik R Dubberke
@en
Erik R Dubberke
@nl
type
label
Erik R Dubberke
@ast
Erik R Dubberke
@en
Erik R Dubberke
@nl
prefLabel
Erik R Dubberke
@ast
Erik R Dubberke
@en
Erik R Dubberke
@nl